-

FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices

  • Clearance expands connectivity and interoperability of the Dexcom CGM digital ecosystem
  • Allows invited third-party developers to connect applications and devices to real-time CGM data
  • Gives Dexcom users more choice in where and how they interact with their glucose data

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today U.S. Food and Drug Administration (FDA) clearance of the Dexcom Partner Web APIs, enabling invited third-party developers to integrate real-time CGM data into their digital health apps and devices.

“FDA clearance of our real-time APIs further solidifies Dexcom as the leader in interoperable CGM, giving Dexcom users even more choice in how they view and interact with their glucose data,” said Jake Leach, chief technology officer at Dexcom. “The new APIs will help seamlessly integrate the power of real-time Dexcom CGM data into some of the leading diabetes and digital health solutions.”

Several prominent diabetes and digital health companies have been invited to access the real-time APIs and are already in the testing and development phase, including Garmin® and Teladoc Health’s Livongo® for Diabetes.

“Garmin welcomes the opportunity to bring Dexcom CGM data to runners, cyclists and everyday users who rely on the technology 24/7 to proactively manage their diabetes,” said Joe Schrick, vice president of fitness at Garmin. “We are proud to be part of this integration that will allow users a secondary way to quickly and discreetly view estimated glucose levels and trends right from their smartwatch at any time.”

People with diabetes and their healthcare providers will benefit from the integration of real-time Dexcom CGM data into third-party apps and devices in a multitude of ways. For example, it will:

  • Allow users to quickly see all their therapy data in one place
  • Empower users to utilize the apps they find most beneficial for a more tailored Dexcom experience
  • Enable in-the-moment diabetes management coaching and feedback

For more information about the Dexcom real-time APIs and other offerings for third-party developers, visit Dexcom.com/WebAPI.

About DexCom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact:
James McIntosh, (619) 884-2118
Dexcom Public Relations
james.mcintosh@dexcom.com

Investor Contact:
Sean Christensen, (858) 203-6657
Dexcom Corporate Affairs
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Summary
FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices
Release Versions
$Cashtags

Contacts

Media Contact:
James McIntosh, (619) 884-2118
Dexcom Public Relations
james.mcintosh@dexcom.com

Investor Contact:
Sean Christensen, (858) 203-6657
Dexcom Corporate Affairs
sean.christensen@dexcom.com

More News From DexCom, Inc.

Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026. Guided directly by H...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as...
Back to Newsroom